Yttrium-90 clinical trials
How each study uses Yttrium-90 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Yttrium-90 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 4
M.D. Anderson Cancer Center (1) · Northwestern University (1) · University Health Network, Toronto (1) · University of Southern California (1)
Studies
Open first, then newest update. How each study uses Yttrium-90 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver MetastasesRecruitingPhase 1M.D. Anderson Cancer CenterNCT05195710Written as Yttrium-90 (Y-90) resin microspheres
- Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-riskRecruitingPhase 2Northwestern UniversityNCT05620771Written as Y90 + Atezolizumab and Bevacizumab
- Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before TransplantRecruitingPhase 1/2University Health Network, TorontoNCT06725121Written as Yttrium-90 (Y-90)
- Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 RadioembolizationWithdrawnNot applicableUniversity of Southern CaliforniaNCT03300401Written as Yttrium-90 (90Y)
Given beside what is tested · 1 — Yttrium-90 is usual care or a partner of the new treatment
Codes
What other systems call Yttrium-90 · ClinicalTrials.gg INT000640
- MeSH (NLM) C000615496Yttrium-90One source NLM
- UNII (FDA) 1K8M7UR6O1YTTRIUM Y-90Confirmed FDA, NLM, Wikidata
- Wikidata Q2650092yttrium-90Confirmed FDA, NLM, Wikidata
- DrugBank DB13076One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615496 | Yttrium-90 | One source NLM |
| UNII (FDA) | 1K8M7UR6O1 | YTTRIUM Y-90 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q2650092 | yttrium-90 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB13076 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.